ViaDerma, Inc., a growing pharmaceutical company established in 2014 by Dr. Christopher Otiko has gain popularity for releasing innovative products in the medicine world. Its accurate and efficient R&D activities have allowed people to get medicines ranging from infectious diseases & pain management.
The year 2020 has turned out to be a breakthrough year for ViaDerma Inc. as the company launched two major pharmaceutical products namely, Vitastem and Liberdol. Irrespective of difficult situations, the pharmaceutical company has managed to approve and launch these two products.
Vitastem is a 55 ml spray bottle that was approved by the FDA after the successful testing of this pharmaceutical product by a large national hospital chain and a major health insurance company. It is suitable for treating a wide variety of skin conditions including large wounds.
It is a topical antibiotic that helps to treat acne, eczema, psoriasis, infections, burns, and wounds. The other product Liberdol is a pain relief product launched in 2020 and it is set to bring a strong revolution in the analgesics market in the US.
For 2021, the company has secured an extended line of credit for financing future manufacturing, and ViaDerma, Inc. expects its sales to cross 500,000 units in 2021. Dr. Christopher Otiko has expressed that they are in the final stages of discussions with a major midwestern university regarding the discussion of their initial purchase of the product, Vitastem.
Additionally, ViaDerma, Inc. has started discussions with a major global medical nonprofit where doctors have expressed their willingness to use Vitastem for treating patients. After seeing the exceptional performance under tough conditions in 2020, ViaDerma, Inc. is all set to make a big jump in terms of its growth in 2021.
